Clinical Trial Search

Primary: Number of TLR4 Signaling Pathway Analytes With a Significant Change in Expression From Baseline (Pre-solar Stimulated Light Exposure to 1 and 24 Hours Post Exposure)…

Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells

Primary: Number of Participants With Severity of Photodamage — 0; 0; 1; 0 Participants

Primary: Changes in Putrescine Over 3 Months — 0.03; 1.45; 0.2 nmol/g skin

Primary: Change in Histopathology Score of Sun Damaged Skin by Treatment Group — 0.4; -0.1; 0.1 units on a scale — p=0.10

Primary: Change From Baseline in Overall Photodamage Score — 5.6; -0.8 score on a scale — p=<0.001

Primary: DNA Damage Level by Cyclobutane Pyrimidine Dimer (CPD) Measurement — 2.48; 2.18; 2.64; 1.14 Optical Density Units — p=0.003

Primary: Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) — 23; 21 genes

Primary: Changes From Baseline in Actinic Keratosis - Lesion Base Count. — 1.15; 2.65; 1.15; 2.60 lesions — p=<0.001

Primary: Number of Participants With Evaluator (Dermatologist) Global Assessment (EGA) Score for Well Tolerance of Product 14 Days Post-Procedure — 36; 38 Participants — p=0.3334

Primary: Change From Baseline in Investigator Global Assessment (IGA) of Participant's Overall Facial Appearance at Week 24 — 6.04; 5.81; 0.6; 0.7 units on scale — p=0.358

Primary: Number of Participants Reporting Product Tolerability Based on Evaluator Global Assessment Scores — 47; 44; 0; 0 Participants

Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants

Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions

Primary: Complete Clearance (%) of Actinic Keratoses (AKs) — 81; 60 percentage (%) of AK clearance

Primary: Change in Scar Pliability Between the Treated and Control Incision Sites as Measured by Skin Elasticity at 6 Months Compared to Baseline

Primary: Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months — 59.1; 72.5 Percent change of AK lesions

Primary: Number of Indoor Tanning Sessions in the Last 30 Days — 1.98; 1.35; 1.92 Sessions in last month

Primary: Sun Stage of Change at 3 Months — 17; 5; 10; 12 Participants

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Median VAS Improvement Score as Assessed by Blinded Physician Reviewers — 1.5 units on a scale — p=<0.0001

Primary: Reduction of Bruising — 3.74; 4.50 cm squared

Primary: Cure Rate — 751 lesions

Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations

Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants

Primary: Prevalence of Sun Protection Practices — 0.30; 0.43; 0.35; 0.41 proportion of practices/day

Primary: Photographic Knee Laxity and Texture Evaluation — 1.87; 2.02 score on a scale

Primary: Change in Aesthetics — 2; 1 score on a scale

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3